A nationwide shortage of attention deficit hyperactivity disorder (ADHD) stimulant medication in 2022-2023 may have been caused by disruptions in the international supply chain.[1] An economic evaluation suggests that overprescribing was not the cause.[1] In 2022-2023, the European Medicines Agency analyzed 83,266 drug shortage notifications from 24 EEA countries.[3] Stimulant medications are the most commonly used medications for ADHD and increase the levels of neurotransmitters in the brain.[1] In the US, approximately 10.5% of children and adolescents had ADHD in 2022, of which 58.1% had a moderate to severe form.[2] Almost 54% of children with ADHD received medication and 44.4% received behavioral treatment.[2] The shortage of medicines in the EU is caused by production problems, quotas for industry, parallel trading and fluctuations in demand.[8]